WAINUA (AUTOINJECTOR) (eplontersen) by AstraZeneca. Approved for transthyretin-directed rna interaction [epc]. First approved in 2023.
Drug data last refreshed 18h ago · AI intelligence enriched 1mo ago
WAINUA (eplontersen) is a subcutaneous oligonucleotide therapeutic approved December 2023 that targets transthyretin through RNA interaction mechanisms. It is designed to treat transthyretin-mediated diseases by modulating gene expression at the RNA level. The autoinjector formulation enhances patient convenience and adherence in chronic disease management.
Early-stage growth product with recent FDA approval positions commercial teams to build market presence and establish formulary relationships in an emerging oligonucleotide space.
Transthyretin-directed RNA Interaction
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
The Eplontersen Pregnancy and Lactation Outcomes Study
A Study to Assess the PK, PD, Safety and Tolerability of Eplontersen in Healthy Chinese Volunteers
EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy
Worked on WAINUA (AUTOINJECTOR) at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moAstraZeneca is hiring 1 role related to this product
WAINUA represents a rare opportunity to join a growth-stage, newly approved oligonucleotide platform with patent protection extending nearly 8 years. Building expertise in RNA therapeutics, rare disease commercialization, and specialty autoinjector markets positions professionals for advancement in AstraZeneca's expanding precision medicine portfolio.